Articles with "ctdna levels" as a keyword



Photo from wikipedia

Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study

Sign Up to like & get
recommendations!
Published in 2017 at "Annals of Oncology"

DOI: 10.1093/annonc/mdx212

Abstract: Background Recent clinical results support the use of new immune checkpoint blockers (ICB), such as anti-PD-1 (e.g. nivolumab and pembrolizumab) and anti-PD-L1 antibodies. Radiological evaluation of ICB efficacy during therapy is challenging due to tumor… read more here.

Keywords: study; ctdna levels; circulating tumor; tumor dna ... See more keywords
Photo from wikipedia

PO-493 ctDNA profiles of metastatic melanoma patients under therapy

Sign Up to like & get
recommendations!
Published in 2018 at "ESMO Open"

DOI: 10.1136/esmoopen-2018-eacr25.995

Abstract: Introduction In precision oncology it is a great interest to develop novel disease and therapy monitoring technologies that are non-invasive and highly sensitive. Specifically, our project aims to establish blood-based assays that allow ‘real-time’ monitoring… read more here.

Keywords: ctdna; disease; ctdna levels; melanoma patients ... See more keywords
Photo from wikipedia

Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma

Sign Up to like & get
recommendations!
Published in 2021 at "Clinical Cancer Research"

DOI: 10.1158/1078-0432.ccr-21-1324

Abstract: Purpose: We evaluated the predictive and prognostic value of circulating tumor DNA (ctDNA) in patients with Ewing sarcoma (EWS) treated in the EWING2008 trial. Experimental Design: Plasma samples from 102 patients with EWS enrolled in… read more here.

Keywords: ctdna levels; response; ctdna; ewing sarcoma ... See more keywords
Photo by maxdcrn from unsplash

Abstract LB289: Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies

Sign Up to like & get
recommendations!
Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-lb289

Abstract: Background: The role of circulating tumor DNA (ctDNA) in monitoring response to immunotherapy in NSCLC is unconfirmed. This is a retrospective analysis of association between longitudinal ctDNA levels and clinical outcomes in 1L TIS (anti-PD-1)… read more here.

Keywords: ctdna; pfs; rationale 304; ctdna levels ... See more keywords
Photo from wikipedia

Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA

Sign Up to like & get
recommendations!
Published in 2022 at "Cancers"

DOI: 10.3390/cancers14102479

Abstract: Simple Summary An early assessment of response to treatment is crucial to informing appropriate therapeutic management. Using a plasma-only strategy, we measured changes in circulating tumor DNA (ctDNA) levels after one or two cycles of… read more here.

Keywords: lung cancer; early assessment; treatment; ctdna levels ... See more keywords